Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT03038880
- Locations
- 🇺🇸
Retinal Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸California Retina Consultants, Bakersfield, California, United States
🇺🇸Rand Eye, Deerfield Beach, Florida, United States
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT02976194
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02878681
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
- Conditions
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02864472
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 3
- Registration Number
- NCT02859441
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 90
- Registration Number
- NCT02857491
- Locations
- 🇨🇳
Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2016-07-25
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Johannes Gutenberg University Mainz
- Target Recruit Count
- 71
- Registration Number
- NCT02843490
- Locations
- 🇩🇪
Clinical Trial Site, Department of Ophthalmology, University Medical Center Johannes Gutenberg University Mainz, Mainz, Germany
Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD
- Conditions
- Interventions
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2016-11-04
- Target Recruit Count
- 115
- Registration Number
- NCT02810808
- Locations
- 🇨🇳
Shanghai Zhongshan Hospital, Shanghai, China
🇨🇳Eye & Ent Hospital of Fudan University, Shanghai, China
🇨🇳Shanghai 10th People's Hospital, Shanghai, China
Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2018-11-30
- Target Recruit Count
- 120
- Registration Number
- NCT02806752
- Locations
- 🇨🇳
Wuhan General Hospital of PLA, Wuhan, Hubei, China
🇨🇳The Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
🇨🇳Shenzhen Aier Eye Hospital, Shenzhen, Guangdong, China
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Ohr Pharmaceutical Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT02727881
- Locations
- 🇺🇸
Investigational Site, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.